Aequus Pharmaceuticals (Aequus Pharmaceuticals) Total Current Assets : $0.36 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Aequus Pharmaceuticals Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Aequus Pharmaceuticals's total current assets for the quarter that ended in Sep. 2023 was $0.36 Mil.

Aequus Pharmaceuticals Total Current Assets Historical Data

The historical data trend for Aequus Pharmaceuticals's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aequus Pharmaceuticals Total Current Assets Chart

Aequus Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Current Assets

Get a 7-Day Free Trial

0.92

0.84

2.16

2.81

0.67

Aequus Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Sep23
Total Current Assets	Get a 7-Day Free Trial															2.23	1.47	0.96	0.67	0.36

Aequus Pharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Aequus Pharmaceuticals's Total Current Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.217	+	0.228	+	0.069	+	0.151
	=	0.67

Aequus Pharmaceuticals's Total Current Assets for the quarter that ended in Sep. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.116	+	0.052	+	0.136	+	0.056
	=	0.36

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Aequus Pharmaceuticals (OTCPK:AQSZF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Aequus Pharmaceuticals's Liquidation Value for the quarter that ended in Sep. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.116	-	3.517	+	0.75 * 0.052	+	0.5 * 0.136
=	-3.29

Aequus Pharmaceuticals Total Current Assets Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Aequus Pharmaceuticals (Aequus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (OTCPK:AQSZF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

AEQ:Germany AQS:Canada

Address

200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4

Website

https://www.aequuspharma.ca

Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.